The mission of post-marketing research has always been to amplify how new pharmaceuticals are evaluated for their cost effectiveness and clinical efficacy. This can be seen in everything from early commercially driven research, which were marked by improvements in safety surveillance reporting, to the adoption of Health Technology Assessment (HTA) and more evidence-based reimbursement evaluations in the last few years.